Bernstein EF, Chan EL Abdominal aortic aneurysm in high-risk patients. Outcome of selective management based on size and expansion rate. Ann Surg. 1984 Sep;200(3):255-63.
Brown PM, Pattenden R, Gutelius JR The selective management of small abdominal aortic aneurysms: the Kingston study. J Vasc Surg. 1992 Jan;15(1):21-5; discussion 25-7.
Castleden WM, Mercer JC Abdominal aortic aneurysms in Western Australia: descriptive epidemiology and patterns of rupture. Br J Surg. 1985 Feb;72(2):109-12.
Chuter T, Hopinson B, Wendt G et al Transfemoral aortic aneurysm repair with bifurcated endovascular grafts. Presented at the 43rd meeting of the International Society for Cardiovascular surgery, North American Chapter, New Orleans, LA June 1995.
Chuter T Presented at III International Endovascular Surgery Symposium, Sydney, Australia, November 1993 and VII International Congress on Endovascular Interventions, Phoenix, Arizona, February 1994.
Limet R, Sakalihassan N, Albert A Determination of the expansion rate and incidence of rupture of abdominal aortic aneurysms. J Vasc Surg. 1991 Oct;14(4):540-8.
Maass D, Zollikofer CL, Largiadèr F, Senning A Radiological follow-up of transluminally inserted vascular endoprostheses: an experimental study using expanding spirals. Radiology. 1984 Sep;152(3):659-63.
Mailhe C Results of the Stentor Trial. Presented at the 17th World Congress of the International Union of Angiology, London, England, April 1995.
Mann ML Complications of endovascular stented grafts for the treatment of arterial lesions: The agony after ecstasy. Presented at the 43rd meeting of the International Society for Cardiovascular Surgery, North American Chapter, New Orleans, LA, June 1994.
Marin ML Stented grafts for the treatment of aorto-iliac and femoropopliteal occlusive disease. Abstract, VII International Congress on Endovascular Interventions, Phoenix, Arizona, February 1994.
May J, White G, Waugh R, Yu W, Harris J Transluminal placement of a prosthetic graft-stent device for treatment of subclavian artery aneurysm. J Vasc Surg. 1993 Dec;18(6):1056-9.
May J, White GH Presented at III International Endovascular Surgery Symposium, Sydney, Australia, November 1993 and VII International Congress on Endovascular Interventions, Phoenix, Arizona, February 1994.
McFarlane MJ The epidemiologic necropsy for abdominal aortic aneurysm. JAMA. 1991 Apr 24;265(16):2085-8.
Parodi J Presented at III International Endovascular Surgery Symposium, Sydney, Australia, November 1993 and VII International Congress on Endovascular Interventions, Phoenix, Arizona, February 1994.
Parodi JC, Palmaz JC, Barone HD Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg. 1991 Nov;5(6):491-9.
Parodi JC Endoluminal treatment of aortic aneurysms. Presented at the 2nd International Workshop on Interventional Radiology, Czech Radiological Society, Prague, June 1995.
Parodi JC Endovascular repair of abdominal aortic aneurysms. Advances in Vascular Surgery 1993; 1:85-106.
Piquet P, Bartoli JM, Rolland PH, Mercier C Tantalum Dacron co-knit stent for endovascular treatment of aorto-iliac aneurysms. Presented at the 17th World Congress of the International Union of Angiology, London, England, April 1995.
Semba CP, Dake MD, Mitchell RS, Miller DC Endovascular grafting for the treatment of thoracic aortic aneurysms: Preliminary experience at Stanford University Medical Center. Abstract, VII International Congress on Endovascular Interventions, Phoenix, Arizona, February 1994.
Suggested standards for reports dealing with lower extremity ischemia Prepared by the Ad Hoc Committee on Reporting Standards, Society for Vascular Surgery/North American Chapter, International Society for Cardiovascular Surgery. J Vasc Surg. 1986 Jul;4(1):80-94. Erratum in: J Vasc Surg 1986 Oct;4(4):350.
Vieth FJ, Mann ML, Panetta TF, Parodi JC, Cinaron J Stented grafts for the treatment of traumatic arterial lesions and non-aortic aneurysms. Abstract, VII International Congress on Endovascular Interventions, Phoenix, Arizona, February 1994.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
